Literature DB >> 7693820

Immunoassays for inhibin and its subunits. Further applications of the synthetic peptide approach.

N Groome1, M O'Brien.   

Abstract

We describe the preparation of a new rat monoclonal antibody (CRC1) to the N-terminal sequence of the 43 kDa subunit of human ovarian inhibin, and its use together with other anti-peptide monoclonal antibodies, in two-site immunoassays for the detection of inhibin-related material in biological fluids. The Fab fraction of a mouse monoclonal antibody (R1) to the N-terminal portion of the 20 kDa alpha subunit, coupled to alkaline phosphatase, was used for detection, and either CRC1 or a monoclonal antibody (E4) to the beta-A subunit were used as capture antibodies. The E4/R1 combination, expected to measure dimeric bioactive inhibin, could detect less than 2 pg/ml of recombinant inhibin in diluent, gave good recovery of activity spiked into human blood, and could measure significant levels of immunoreactivity in sera from women undergoing ovulation induction, and in some normal women. Sera from post-menopausal women contained undetectable levels. Apparent inhibin levels in human follicular fluid were increased six-fold by pretreatment with 8 M urea, suggesting masking of epitopes in this fluid. Activin cross-reactivity in the assay was 0.05%. The R1/CRC1 assay, expected to measure only large molecular weight forms of inhibin or its alpha subunit, could detect immunoreactivity in human FF diluted 50,000-fold, and in all sera tested, although the levels in the hyperovulated women were higher. By contrast to the E4/R1 assay much of the immunoreactivity was labile during the clotting process, or subsequent assay, and reliable measurements on blood with this assay will require special sample collection procedures. These results demonstrate the value of anti-peptide monoclonal antibodies in the study of inhibin, and the results obtained with CRC1 show that antibodies useful for immunoassays can sometimes be obtained without the purified target molecule being available for immunization or screening.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693820     DOI: 10.1016/0022-1759(93)90342-5

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  6 in total

Review 1.  The normal human menstrual cycle.

Authors:  N Chabbert-Buffet; P Bouchard
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

2.  Recombinant human follicle-stimulating hormone for ovulation induction in polycystic ovary syndrome: a prospective, randomized trial of two starting doses in a chronic low-dose step-up protocol.

Authors:  J Balasch; F Fábregues; M Creus; R Casamitjana; B Puerto; J A Vanrell
Journal:  J Assist Reprod Genet       Date:  2000-11       Impact factor: 3.412

3.  Serum inhibin-b in fertile men is strongly correlated with low but not high sperm counts: a coordinated study of 1,797 European and US men.

Authors:  Niels Jørgensen; Fan Liu; Anna-Maria Andersson; Matti Vierula; D Stewart Irvine; Jacques Auger; Charlene K Brazil; Erma Z Drobnis; Tina K Jensen; Pierre Jouannet; James W Overstreet; J Bruce Redmon; Amy Sparks; Jorma Toppari; Christina Wang; Niels E Skakkebæk; Shanna H Swan
Journal:  Fertil Steril       Date:  2010-02-10       Impact factor: 7.329

4.  Identification of biologically active inhibin in the peritoneal fluid of women.

Authors:  R B Billiar; R Hemmings; P Smith; N Groome
Journal:  J Assist Reprod Genet       Date:  1995-01       Impact factor: 3.412

5.  Follicular development and hormonal levels following highly purified or recombinant follicle-stimulating hormone administration in ovulatory women and WHO group II anovulatory infertile patients.

Authors:  J Balasch; F Fábregues; J Peñarrubia; M Creus; R Vidal; R Casamitjana; D Manau; J A Vanrell
Journal:  J Assist Reprod Genet       Date:  1998-10       Impact factor: 3.412

6.  Inhibin as a marker for ovarian cancer.

Authors:  I Cooke; M O'Brien; F M Charnock; N Groome; T S Ganesan
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.